Immunotherapy resistance is a reality for many cancer patients. Three tumor-intrinsic molecular pathways, β-catenin, PPARγ, and FGFR3, were identified and linked to the exclusion of T cells from urothelial tumors. Targeting these pathways may enhance immune checkpoint efficacy.
Table of Contents
- Priority BriefsAmanda Shreders, Richard Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman and Douglas B. JohnsonCancer Immunol Res July 1 2016 4 (7) 569-573; DOI:10.1158/2326-6066.CIR-15-0281
Anti–PD-1 therapies are becoming first-line treatments for metastatic melanoma, but how prior immune therapy affects anti–PD-1 efficacy is unknown. Prior ipilimumab was found to predict response to anti–PD-1, which could help select patients for therapy.
- Research ArticlesTakahiro Kamiya, Yu-Hsiang Chang and Dario CampanaCancer Immunol Res July 1 2016 4 (7) 574-581; DOI:10.1158/2326-6066.CIR-15-0229
Hepatocellular carcinoma (HCC) is often incurable. Human NK cells with enhanced cytotoxicity against HCC were expanded in vitro, generating efficient killers of HCC in culture and in mice, supporting the infusion of such cells for treatment of HCC.
- Research ArticlesImmune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant ChemotherapyPhilip D. Dunne, Darragh G. McArt, Paul G. O'Reilly, Helen G. Coleman, Wendy L. Allen, Maurice Loughrey, Sandra Van Schaeybroeck, Simon McDade, Manuel Salto-Tellez, Daniel B. Longley, Mark Lawler and Patrick G. JohnstonCancer Immunol Res July 1 2016 4 (7) 582-591; DOI:10.1158/2326-6066.CIR-15-0302
A subgroup of patients with colorectal cancer was defined by high PD-L1 gene expression on their tumor-infiltrating immune cells. These patients may be harmed by standard chemotherapy and may benefit from immunotherapy that targets the PD-1 immune checkpoint.
- Research ArticlesPretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer PatientsKohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Kazunori Aoki, Nobuyoshi Hiraoka, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Yuji Heike and Tetsuya HamaguchiCancer Immunol Res July 1 2016 4 (7) 592-599; DOI:10.1158/2326-6066.CIR-15-0298
It was not clear whether immune cell subsets in peripheral blood have prognostic value for patients about to undergo first-line chemotherapy. This prospective study reveals an immune signature that correlates with significantly longer progression-free survival.
- Research Articles | AuthorChoiceLance D. Miller, Jeff A. Chou, Michael A. Black, Cristin Print, Julia Chifman, Angela Alistar, Thomas Putti, Xiaobo Zhou, Davide Bedognetti, Wouter Hendrickx, Ashok Pullikuth, Jonathan Rennhack, Eran R. Andrechek, Sandra Demaria, Ena Wang and Francesco M. MarincolaCancer Immunol Res July 1 2016 4 (7) 600-610; DOI:10.1158/2326-6066.CIR-15-0149
Assessment of expression profiles and clinical data from many breast tumors enabled classifications having prognostic value. Tumors comprising molecularly distinct subtypes differed in potential for metastasis-protective immune responsiveness, perhaps reflecting a differential activation of immunomodulatory pathways
- Research ArticlesEllen C. Moore, Harrison A. Cash, Andria M. Caruso, Ravindra Uppaluri, James W. Hodge, Carter Van Waes and Clint T. AllenCancer Immunol Res July 1 2016 4 (7) 611-620; DOI:10.1158/2326-6066.CIR-15-0252
Inhibition of mTOR is felt to be systemically immunosuppressive. However, the antitumor immunity induced by checkpoint inhibition in an immunogenic model of oral cavity cancer was enhanced by the mTOR inhibitor rapamycin via a T cell–dependent mechanism.
- Research ArticlesAntitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T CellsSimon J. Dovedi, Grazyna Lipowska-Bhalla, Stephen A. Beers, Eleanor J. Cheadle, Lijun Mu, Martin J. Glennie, Timothy M. Illidge and Jamie HoneychurchCancer Immunol Res July 1 2016 4 (7) 621-630; DOI:10.1158/2326-6066.CIR-15-0253
Radiotherapy plus CD40 or TLR7 stimulation leads to long-term clearance of B- and T-cell lymphomas. These curative responses after combining radiotherapy with an immunomodulatory agent depended upon the priming of tumor-specific CD8+ T cells by dendritic cells.
- Research ArticlesHong Xu, Hongfen Guo, Irene Y. Cheung and Nai-Kong V. CheungCancer Immunol Res July 1 2016 4 (7) 631-638; DOI:10.1158/2326-6066.CIR-15-0221
Most effective antibody immunotherapy relies on ADCC. A potent ADCC-enhanced antibody is described that, in comparison with Abs with altered affinities for Fc receptors, significantly improved the growth control of tumors expressing cancer-antigen GD2.
- AddendumADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B CellsEugenia Zah, Meng-Yin Lin, Anne Silva-Benedict, Michael C. Jensen and Yvonne Y. ChenCancer Immunol Res July 1 2016 4 (7) 639-641; DOI:10.1158/2326-6066.CIR-16-0108